Functional quantification of DNA-binding proteins p53 and estrogen receptor in cells and tumor tissues by DNA affinity immunoblotting

Cancer Research

Volumn 61, Issue 14, 2001, Pages 5402-5406

  Liu, Yuangang ^a   Asch, Harold ^b   Kulesz Martin, Molly F ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA BINDING PROTEIN; ESTROGEN RECEPTOR; PROTEIN P53;

AFFINITY CHROMATOGRAPHY; ARTICLE; CANCER CHEMOTHERAPY; DNA BINDING; DNA PROBE; EMBRYO; GENE EXPRESSION; GENE MUTATION; GENOTYPE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN DNA BINDING; TUMOR CELL; TUMOR SUPPRESSOR GENE;

ANIMALS; BINDING, COMPETITIVE; BREAST NEOPLASMS; DNA; DNA-BINDING PROTEINS; GENOTYPE; HUMANS; IMMUNOBLOTTING; PROTEIN BINDING; RECEPTORS, ESTROGEN; REPRODUCIBILITY OF RESULTS; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0035878718     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Clinical implications of the p53 tumor-suppressor gene
2. DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2
3. Activation of the ATM kinase by ionizing radiation and phosphorylation of p53
4. Enhanced phosphorylation of p53 by ATM in response to DNA damage
5. Regulation of specific DNA binding by p53: Evidence for a role for O-glycosylation and charged residues at the carboxy-terminus
6. Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain
7. A viral mechanism for inhibition of p300 and PCAF acetyltransferase activity
8. Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53
9. Regulation of p53 stability by Mdm2
10. Mdm2 promotes the rapid degradation of p53
11. Sequence-specific, D. N. A. Binding by p53: Identification of target sites and lack of binding to p53-MDM2 complexes
12. p53 Mutation, and MDM2 amplification in human soft tissue sarcomas
13. Abnormal expression of MDM-2 in breast carcinomas
14. Role of the human papillomaviruses in human cancer
15. Functional inactivation but not structural mutation of p53 causes liver cancer
16. Identification of the p53 protein domain involved in formation of the simian virus 40 large T-antigen-p53 protein complex
17. Maintenance of p53 alterations throughout breast cancer progression
18. Correlations between estrogen receptor, progesterone receptor, and patient characteristics in human breast cancer
19. Prognostic and predictive value of p53 and p21 in breast cancer
20. p53 in tumour pathology: Can we trust immunohistochemistry?
21. The p53 gene in breast cancer: Prognostic value of complementary DNA sequencing versus immunohistochemistry
22. A simple p53 functional assay for screening cell lines, blood, and tumors
23. Inactivation of the p53 pathway in prostate cancer: Impact on tumor progression
24. p53 alterations in recurrent squamous cell cancer of the head and neck refractory to radiotherapy
25. Inactivation of the p53 protein in cell lines derived from human esophageal cancers
26. Mouse cell clones for improved quantitation of carcinogen-induced altered differentiation
27. Morphological and functional properties of TM preneoplastic mammary outgrowths
28. Activities and response to DNA damage of latent and active sequence-specific DNA binding forms of mouse p53
29. WAFI, a potential mediator of p53 tumor suppression
30. An estrogen-responsive element derived from the 5′ flanking region of the Xenopus vitellogenin A2 gene functions in transfected human cells
31. Affinity purification of sequence-specific DNA binding proteins
32. Western blotting": Electrophoretic transfer of proteins from sodium dodecyl sulfate-polyacrylamide gels to unmodified nitrocellulose and radiographic detection with antibody and radioiodinated protein A
33. Wild-type alternatively spliced p53: Binding to DNA and interaction with the major p53 protein in vitro and in cells
34. Transactivational, and, D. N. A. Binding abilities of endogenous p53 in p53 mutant cell lines
35. p53 mutations selected in vivo when mouse mammary epithelial cells form hyperplastic outgrowths are not necessary for establishment of mammary cell lines in vitro
36. Clinical implications of p53 mutations
37. DNA strand breaks: The DNA template alterations that trigger p53-dependent DNA damage response pathways
38. Stabilization of wild-type p53 by hypoxia-inducible factor 1α
39. Redox modulation of p53 conformation and sequence-specific DNA binding in vitro